NMDA receptor pathways as drug targets

@article{Kemp2002NMDARP,
  title={NMDA receptor pathways as drug targets},
  author={John A. Kemp and Ruth M. Mckernan},
  journal={Nature Neuroscience},
  year={2002},
  volume={5 Suppl 1},
  pages={1039-1042}
}
Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease… 
Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
  • S. Lipton
  • Biology
    Nature Reviews Drug Discovery
  • 2006
TLDR
The molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca2+ influx through the receptor's associated ion channel and consequent free-radical formation is reviewed.
Amide-containing NR2B/NMDA receptor antagonists
TLDR
This article will focus on a recent series of NR2B antagonists from Pfizer that show good selectivity over dofetilide binding.
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
  • K. Gogas
  • Biology
    Current opinion in pharmacology
  • 2006
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
  • S. Lipton
  • Biology
    Journal of Alzheimer's disease : JAD
  • 2004
TLDR
Clinical use has corroborated the prediction that memantine is thus well tolerated and a series of second-generation memantine derivatives are currently in development and may prove to have even greater neuroprotective properties than memantine.
Mechanism-based targeting of NMDA receptor functions
  • G. Popescu
  • Biology
    Cellular and Molecular Life Sciences CMLS
  • 2005
Abstract.NMDA receptors (NRs) are key signaling proteins in the central nervous system and represent important targets for drug development in several neurologic disorders. They are critically
Review Mechanism-based targeting of NMDA receptor functions
NMDA receptors (NRs) are key signaling proteins in the central nervous system and represent important targets for drug development in several neurologic disorders. They are critically involved with
Pathologically activated therapeutics for neuroprotection
  • S. Lipton
  • Biology, Psychology
    Nature Reviews Neuroscience
  • 2007
TLDR
This article describes a series of strategies for the development of neuroprotective therapeutics that are both effective and well tolerated, based on the principle that drugs should be activated by the pathological state that they are intended to inhibit.
Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists.
TLDR
The improved therapeutic index of these compounds is expected to be the result of the subtype selectivity and cellular location of the NR2B receptors within the CNS.
Clinically Tolerated Strategies for NMDA Receptor Antagonism
TLDR
This chapter reviews the logical process that was applied over the last decade to develop memantine as the first clinically tolerated yet effective agent against NMDAR-mediated neurotoxicity.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
NMDA receptor antagonists as analgesics: focus on the NR2B subtype.
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
TLDR
This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists, and consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.
Glycine-site antagonists and stroke.
TLDR
This review focuses on the strychnine insensitive glycine binding site located on the NMDA receptor channel, and on the possible use of selective antagonists for the treatment of stroke.
Glutamatergic mechanisms in schizophrenia.
  • G. Tsai, J. Coyle
  • Psychology, Medicine
    Annual review of pharmacology and toxicology
  • 2002
TLDR
Clinical trials indicate agents that enhance NMDA receptor function via the glycine modulatory site reduce negative and variably improve cognitive function in schizophrenics receiving typical antipsychotic medications.
NMDA receptors as targets for drug action in neuropathic pain.
  • C. Parsons
  • Biology
    European journal of pharmacology
  • 2001
Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy *
  • Michael Davis
  • Biology, Psychology
    The European journal of neuroscience
  • 2002
TLDR
Therapeutic interventions based on extinction procedures are commonly used to treat fear disorders, and d‐cycloserine is a widely available and safe compound, which might be usefully combined with traditional extinction‐based approaches in the treatment of clinical fear.
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
TLDR
It appears that the denervation or intermittent stimulation of striatal dopaminergic receptors differentially activates signal transduction pathways in medium spiny neurons, which modify the phosphorylation state of ionotropic glutamate receptors and consequently their sensitivity to cortical input.
Schizophrenia and glutamatergic transmission.
  • C. Tamminga
  • Psychology, Medicine
    Critical reviews in neurobiology
  • 1998
TLDR
A "working" glutamate hypothesis of schizophrenia is proposed which postulates a diminished glutamatergic transmission in the hippocampal glutamate-mediated efferent pathways and cerebral dysfunction in the hippocampus and its target areas, especially the anterior cingulate cortex.
Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
TLDR
Gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months and no statistically significant difference in 3-month survival was observed using Kaplan-Meier curves.
...
1
2
3
4
5
...